Matthew Hawryluk, PhD

Dr. Matthew J. Hawryluk joined Prime Medicine in 2025 as Chief Business Officer. He is a biotechnology executive with a proven track record of building and scaling platform-based companies, securing significant financings, and forging transformative partnerships that advance breakthrough science into meaningful medicines for patients. Before joining Prime Medicine, Dr. Hawryluk served as Chief Business Officer at AIRNA Corporation, an RNA-editing company, where he led corporate and business development, finance, and legal functions. Previously, he spent nearly a decade at Gritstone bio, Inc. (NASDAQ: GRTS), where he served as Executive Vice President and Chief Business Officer, Head of Legal, and Boston Site Head. At Gritstone, he helped build and scale the company’s immunotherapy and vaccine platforms for cancer and infectious diseases, raised more than $640 million across multiple financings, and led strategic partnerships with organizations such as Gilead, BARDA, bluebird bio, the Gates Foundation, and CEPI. Earlier in his career, Dr. Hawryluk held positions of increasing responsibility at Foundation Medicine, Inc. (NASDAQ: FMI), where he built and led the BioPharma business, driving the company’s growth and acquisition by Roche. He also held business development and strategy roles at Thermo Fisher Scientific, Inc. Dr. Hawryluk currently serves on the boards of Axe Compute, Inc. (NASDAQ: AGPU), previously known as Predictive Oncology, and Ourotech, Inc. He has been recognized by PharmaVoice as one of its 100 Standout Executives and by Pharmaceutical Executive magazine as an Emerging Pharma Leader. Dr. Hawryluk holds a B.S. in Biochemistry from the University of Notre Dame, a PhD in Cell Biology and Protein Biochemistry from the University of Pittsburgh School of Medicine, and an MBA from Carnegie Mellon University’s Tepper School of Business.